Karyopharm Therapeutics reaches restructuring agreement with lenders, clearing path for Ayrmid merger

Karyopharm Therapeutics entered a restructuring agreement with its lenders, clearing the path for a merger with Ayrmid. The company secured commitments for up to $55 million of debtor-in-possession financing.

Detected & updated continuously · Source: Nebula